NEKTAR THERAPEUTICS — Director's Dealing 2017

Oct 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-10-05

Reporting Person: Hora Maninder (SVP Pharma Dev & Mfg Ops)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-05	Common Stock	M	7583	$10.69	Acquired	65816	Direct
2017-10-05	Common Stock	S	7583	$25.00	Disposed	58233	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-05	Stock Option	$10.69	M	7583	Disposed	2019-02-07	Common Stock (7583)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring on February 7, 2019.

F2: This number includes 6,000 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).

F3: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.